PL02.06 First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival
2025 · Journal of Thoracic Oncology · 7 citations
https://doi.org/10.1016/j.jtho.2025.09.015
D
D. Planchard
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
13
Papers
68
Citations
6
h-index
3
i10-index
D. Planchard is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & HER2/EGFR in Cancer Research & Gastric Cancer Management and Outcomes. The author has an h-index of 6, co-authored 12 publications.
Papers by this author
worksEP.12.36 Data Visualization of Treatment Patterns in Adults With BRAFV600EMutant mNSCLC in Real-World Settings
2025 · Journal of Thoracic Oncology · 0 citations
https://doi.org/10.1016/j.jtho.2025.09.1566
2798eTiP A phase Ib/II study assessing [177Lu]Lu-DOTA-TATE plus standard of care as a first-line treatment for patients with extensive-stage small cell lung cancer
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.3409
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat